Abstract: Silk fibroin nanoparticles were prepared in the present study based on phase separation between silk fibroin and polyvinyl alcohol. The drug encapsulation efficiency of the prepared nanoparticles was examined at a range of concentrations from 10 ppm to 500 ppm for pramipexole, curcumin, and propranolol hydrochloride. Silk fibroin nanoparticles encapsulated with propranolol presented the highest drug release profile. In order to improve the drug encapsulation efficiency and drug release performance, a modification of silk fibroin nanoparticles with bovine serum albumin and magnetic nanoparticles was tried. The modification was found to improve the drug encapsulation and release of the modified nanoparticles. Bovine-serum-modified nanoparticles presented the best improvement.
Introduction
Drug delivery aims to bring the compound with pharmaceutical activity to the exact point of need in the organism with the right concentrations in order to increase the efficiency of action [1] . The improvement of cellular uptake, the reduction of the side effects, the control of drug release, the enhancement of drug bioavailability, and the reduction of the drug degradation rate are the purposes of drug delivery systems [2] . Recently, nanoparticles are considered to be suitable for drug delivery due to their ability to act as modifiable platforms, their tunable size, and their high surface-to-volume ratio [2] . In addition, they can be used to deliver hydrophilic and hydrophobic drug molecules as well [3] .
Silk fibroin, from the silk worm Bombyx mori, consists of hydrophobic and hydrophilic regions [2] . The hydrophobic domains, i.e., protein crystals and beta sheets, are dominated by repeats of alanine, glycine-alanine, and glycine-alanine-serine. Recently, silk fibroin, due to its excellent properties, such as biocompatibility, biodegradability, and low immunogenicity, has been extensively tested for a drug delivery application since silk materials exhibit high encapsulation efficiency and controllable drug release kinetics [4] [5] [6] .
Bovine serum albumin (BSA) is a water-soluble protein with a well-defined structure. Positively or negatively charged drug molecules can be non-covalently bound to the charged amino acids of albumin. Silk fibroin contains hydrophobic amino acids that could create strong electrostatic interactions through the amino acids' carboxyl groups and the amino groups of bovine serum albumin. These interactions prevent leakage of hydrophobic drugs from bovine serum albumin; thereby, it is expected to improve drug encapsulation, delivery to affected body areas, and drug release rate [7] . Albumin was found to enable the localization of drug carriers in specific tissues (i.e., liver and heart tissues), regulating in this way biodistribution and drug release [8] . Besides this, it was shown that readily available and inexpensive serum albumin can overcome many drugs' shortcomings, such as insolubility, instability in biological environments, poor uptake into cells and tissues, sub-optimal selectivity for targets, and unwanted side effects [9] .
Additionally, magnetic carriers and external magnetic fields that focalize on tumors have emerged as a hopeful strategy to enhance drug accumulation at tumor sites. Magnetic targeting has the advantage of not requiring complex chemical modification of targeting ligands on the surface of nanocarriers when compared with conventional tumor targeting. Exploiting a magnetic field as a driving force represents a noninvasive therapeutic approach [10, 11] .
In the present study, we report aqueous-based preparation methods for silk fibroin nanoparticles, based on phase separation between silk fibroin and polyvinyl alcohol (PVA), with a simple, inexpensive, and appropriate method for pharmaceutical and biomedical applications of drug delivery. Curcumin, pramipexole, and propranolol hydrochloride were chosen as model drugs in this study for their different molecular weights (MWs), surface chemistries, and disease targets. Curcumin, a natural compound with diphenolic groups, is extracted from the rhizome of turmeric. It has been used in clinical trials for cancer therapy [12, 13] . Propranolol is a non-selective beta adrenergic blocking agent and has been used in the treatment of hypertension, angina pectoris, and many other cardiovascular disorders [14] . Pramipexole is a potent dopamine D 2 agonist with a preference for D 3 receptors and is approved worldwide for the treatment of Parkinson's disease symptoms [15] .
Moreover, nanoparticles of silk fibroin were modified with bovine serum albumin for the enrichment of silk fibroin with the above-mentioned properties of albumin [7] [8] [9] . Silk fibroin-bovine serum albumin nanoparticles were prepared since bovine serum albumin has been found to be biocompatible, biodegradable, non-toxic, and non-immunogenic and has interesting results in drug encapsulation and release [16] . Finally, magnetic silk fibroin nanoparticles were also prepared and examined to identify the contribution of magnetic nanoparticles to the encapsulation efficiency and in vitro drug release of the model drugs.
Materials and Methods

Materials
Polyvinyl alcohol high molecular weight solid, (PVA 98-99 hydrolized) and curcumin (95% total curcuminoid content) from Tumeric rhizome were purchased from A Johnson Company (New Brunswick, NJ, USA). Ethanol, Lithium Bromide 99%, and Bovine Serum Albumin (BSA) (lyophilized powder, 66.000 kDa), were purchased from Sigma-Aldrich (St. Louis, MO, USA). Propranolol hydrochloride and Pramipexole were purchased from Fagron Hellas (Trikala, Greece). FeCl 3 •6H 2 O, FeCl 2 •4H 2 O, and NH 4 OH of analytical grade were purchased from Sigma-Aldrich.
Methods
Preparation of Silk Fibroin Solution
Silk fibroin aqueous solution was prepared according to described protocols [17] . Briefly, 5 g cocoons of Bombyx mori were boiled in 2 L of an aqueous solution of sodium carbonate (0.02 M) for 30 min and the degummed silk fibroin was thoroughly rinsed with deionized water, air dried overnight, and then dissolved in a 9.3 M LiBr solution at 60 • C. The solution was dialyzed against deionized water using Slide-a-Lyzer dialysis cassettes (MWCO 3.500, Pierce, Thermo-Fischer Scientific, Waltham, MA, USA) for 2 days for salt removal. In order to clean the solution from impurities, silk aggregates, and debris of cocoons, the silk fibroin solution was centrifuged twice at 9000 rpm for 30 min. The prepared silk fibroin solution was stored at 4 • C for further use.
Preparation of Silk Fibroin (SF) Nanoparticles
Silk fibroin particles were prepared according to the following method [18] : 5 mL of silk fibroin solution was mixed with 2 mL ethanol with a sample pipette and then vortexed for 10 s. Subsequently, 50 mL of 5% PVA solution were added to the fibroin/ethanol mixture and vortexed for 10 s. The fibroin/ethanol/PVA solution mixture was refrigerated for 24 h and centrifuged. In order to remove PVA and ethanol from the nanoparticles, the mixture was washed with deionized water three times and centrifuged after each wash [18] .
Preparation of Silk Fibroin-Bovine Serum Albumin (SF-BSA) Nanoparticles
For the preparation of the Silk Fibroin-Bovine Serum Albumin nanoparticles (SF-BSA-NPs), 2.5 mL of the silk fibroin solution were mixed with 2.5 mL of 2% BSA solution and then the mixture was stirred for 15-20 min. The SF-BSA-NPs were prepared following the method used to prepare the silk fibroin nanoparticles.
Synthesis of Fe 3 O 4 Nanoparticles
For the preparation of the magnetic silk fibroin nanoparticles (SFm-NPs), the magnetic material used was magnetite nanoparticles (Fe 3 O 4 ) prepared in the laboratory. The Fe 3 O 4 nanoparticles were prepared according to the modified Massart method [19] For the preparation of the magnetic silk fibroin nanoparticles (SFm-NPs), 0.1 g Fe 3 O 4 was added to 5 mL of silk fibroin solution followed by the preparation of nanoparticles as above described.
Preparation of Drug-Encapsulated Silk Fibroin Nanoparticles
Curcumin (MW = 368.39 g/mol), propranolol hydrochloride (MW = 259.34 g/mol), and pramipexole (MW = 211.32 g/mol) were the model drugs tested for the encapsulation in the silk fibroin nanoparticles; the chemical formulas of the drugs are presented in Table 1 .
Amounts of the pramipexole and propranolol were dissolved in deionized water and mixed with 5 mL of the silk fibroin solution; curcumin was dissolved in ethanol and then mixed with 5 mL of the silk fibroin solution. Different amounts of the drugs were estimated for the preparation of solutions with concentrations of 10, 35, 50, 100, 200, and 500 ppm for each drug. Finally, the drug-encapsulated silk fibroin nanoparticles were prepared as previously described.
The encapsulation efficiency in the silk fibroin nanoparticles was determined by measuring the UV-vis absorbance (HITACHI U-2000) of the supernatant after the centrifugation that follows the formation of silk fibroin nanoparticles at 430, 265, and 235 nm for curcumin, pramipexole, and propranolol, respectively. Standard calibration curves of model drugs were used for drug quantification (r 2 ≥ 0.999). All experiments were performed in triplicate and the mean value is presented. The difference between the total amount of drug used in the experiment and the amount that remained in the supernatants was expressed as encapsulation efficiency (EE) in silk fibroin nanoparticles [20] and determined by the following equation:
Encapsulation Efficiency = amount of drug that remained in the particles total amount of drug used × 100 (1) 
Silk Fibroin Nanoparticles Characterization
For the identification of the crystalline phase of silk fibroin nanoparticles, X-ray powder diffraction (XRD) patterns were recorded on a Philips PW 1820 diffractometer (Amsterdam, The Netherlands) with Cu Kα radiation from 20 • to 60 • . The morphology of silk fibroin nanoparticles as well as that of drug-encapsulated silk fibroin nanoparticles was imaged using a JEOL JMS-840A scanning electron microscope (JEOL, Tokyo, Japan). The control samples of silk fibroin nanoparticles suspensions in water, the samples of SF-BSA-NPs and SFm-NPs, and their respective drug-encapsulated nanoparticles suspensions in water were lyophilized and the powder obtained was subjected to Fourier Transform Infrared measurement using a Perkin-Elmer FTIR spectrophotometer (model Spectrum 1000, Rodgau, Germany). Nanoparticle size, size distribution, and surface charges of the nanoparticles, and those of their respective drug-encapsulated nanoparticles, were determined by Dynamic Light Scattering (DLS) with a NanoBrook ZetaPALS Brookhaven Instruments (Holtsville, NY, USA) equipped with a diode laser (wavelength, λ = 532 nm). Hysteresis loops for the SF-magnetite nanoparticles were recorded with an Oxford 1.2 H/CF/HT vibrating sample magnetometer (VSM).
In Vitro Drug Release
The amount of drug released in vitro from the drug-encapsulated silk fibroin nanoparticles, at specific time intervals, was calculated as follows: 4 mL of the drug-encapsulated nanoparticles were added to 20 mL of phosphate buffer saline (PBS) at pH 7.4 and shaken at a rate of 120 rpm at 37 • C. At specified time intervals, 2 mL were sampled and centrifuged at 9000 rpm for 10 min. The concentration of the drug in the supernatant was measured by UV-vis spectrometry at 430, 265, and 235 nm for curcumin, pramipexole, and propranolol, respectively. The percentage release was determined as the ratio of the measured amount of the drug released at different time intervals to the initial amount of drug encapsulated in the nanoparticles [12] . All experiments were performed in triplicate and the mean value is presented.
Results and Discussion
Weighting the residual solid of a certain known volume of silk solution after drying at 60 • C, the concentration of the silk fibroin aqueous solution prepared was found to be approximately 4.6% (w/v).
3.1. XRD Characterization, Morphology, and FTIR Characterization of the Silk Fibroin Nanoparticles XRD peaks of silk fibroin are associated with its crystalline structure; Figure 1 presents the XRD results of the silk fibroin nanoparticles prepared in the current study. The 2θ diffraction peak presented in the XRD pattern of the silk fibroin nanoparticles at 2θ = 19.2 • could be attributed to the silk II crystal structure of fibroin, indicating an increased crystallization degree of silk fibroin in the nanoparticles [21, 22] . The morphology of silk fibroin nanoparticles was illustrated by SEM images and is presented in Figure 2a . The nanoparticles observed presented a spherical and/or cylindrical shape with an average mean diameter of about 290 nm. Silk fibroin nanoparticles previously prepared with the same method by Shi et al. [18] presented an average diameter of about 686.5 nm as estimated by SEM image. This difference in size could be attributed to the lower concentration (4%) of silk fibroin solution that was used in this study to prepare the silk fibroin nanoparticles compared to the study by Shi et al. (6%). According to Zhao et al., the increase of the starting silk fibroin solution concentration has an effect on the particle size increase [23] . In Figure 3 , the FTIR spectrum of the prepared silk fibroin nanoparticles is presented. The characteristic peak at 1632 cm −1 attributed to an amide I β-sheet and the peak at 1260 cm −1 attributed to amide III are due to random coil. So, when the nanoparticles of silk fibroin were formed both the silk I crystal structure and the silk II crystal structure of silk fibroin were observed [24, 25] . The assignments of the FTIR bands of silk fibroin nanoparticles are presented in detail in Table 2 . 
Encapsulation Efficiency
The encapsulation efficiency (EE) of the silk fibroin nanoparticles for the three model drugs was studied at a range of concentrations from 10 to 500 ppm. For the curcumin-encapsulated silk fibroin nanoparticles the highest EE was found to be 98 ± 2% and was achieved at 500 ppm, for propranolol the highest EE was 69 ± 3% at 50 ppm and for pramipexole the highest EE was 68 ± 2% at 35 ppm (data not shown).
Size, ζ-Potential, Morphology, and FTIR Characterization of Silk Fibroin Nanoparticles and Drug-Encapsulated Silk Fibroin Nanoparticles
The size of silk fibroin nanoparticles measured by DLS is presented in Table 3 . As seen in the Table, the average diameter of the silk fibroin nanoparticles was found to be 301 ± 11 nm, which is consistent with the size estimated by SEM; the average size was found to increase after the encapsulation of the model drugs (curcumin, pramipexole, and propranolol) in the silk fibroin nanoparticles. The polydispersity index, ranging from 0.10 to 0.25, revealed a uniform particle distribution. The surface charge of the silk fibroin solution, of the drug solutions, of the silk fibroin nanoparticles, and of the silk fibroin nanoparticles encapsulated with the model drugs was determined by ζ-potential and the results are presented in Table 4 . For all samples, the ζ-potential was negative; it was observed that the ζ-potential of propranolol-encapsulated silk fibroin nanoparticles (SF-propranolol NPs) was higher than that of curcumin (SF-curcumin NPs) and pramipexole-encapsulated silk fibroin nanoparticles (SF-pramipexole NPs), leading to the conclusion that propranolol was encapsulated in the center of the silk fibroin nanoparticles while curcumin and pramipexol were adsorbed on the surface of the nanoparticles. The morphology of drug-encapsulated silk nanoparticles, and that of the silk nanoparticles for the sake of comparison, was illustrated by SEM images (Figure 2 ). The nanoparticles observed presented a spherical and/or cylindrical shape with an average mean diameter of 290 nm. As expected, the size of silk fibroin nanoparticles increased after drug encapsulation. The mean diameter of the drug-encapsulated silk fibroin nanoparticles, as estimated from the SEM images, was 490, 392, and 294 nm for propranolol-, pramipexole-, and curcumin-encapsulated silk fibroin nanoparticles, respectively. It is worth noting that these results for nanoparticle sizes are relatively smaller than those measured with DLS; this can be attributed to the dry state of the nanoparticles when measured with SEM.
In Figure 3 , the FTIR spectra of silk fibroin nanoparticles and of drug-encapsulated silk fibroin nanoparticles are presented. In the spectra of the curcumin-encapsulated silk fibroin nanoparticles, it was observed that certain characteristic peaks of the original curcumin were either not evident or exhibited a slight shift or alteration, which demonstrated that certain structural changes and chemical reactions may have occurred between the curcumin and the silk fibroin [12, 27] . Curcumin showed its characteristic group absorption peaks in sharp absorption bands at 1605 cm −1 , 1502 cm −1 (-C=O and -C-C vibrations), 1435 cm −1 (an olefinic -C-H bending vibration), 1285 cm −1 (an aromatic -C-O stretching vibration), and 833 cm −1 (a C-H bond of alkene group) [12, 27] . In addition, propranolol exhibited characteristic peaks in sharp absorption bands at 1680-1620 cm −1 (C=C stretching) and 1260-1000 cm −1 (C-O stretching) [28] . On the contrary, the FTIR spectrum of pramipexole-encapsulated fibroin nanoparticles presented no difference compared to pure fibroin nanoparticles; the characteristic peaks of pramipexol were not evident, leading to the conclusion that after encapsulation with pramipexole the chemical bonding remained unchanged [29] . The assignments of the FTIR bands of silk fibroin nanoparticles as well as those of the drug-encapsulated silk fibroin nanoparticles are presented in detail in Table 4 .
In Vitro Drug Release
The drug release profile, presented in Figure 4 , indicated that the encapsulated curcumin and pramipexole silk fibroin nanoparticles had a short and low-level release percentage, about 1.2% and 0.25%, respectively (presented also in the insets of the Figure 4) while the propranolol-encapsulated silk fibroin nanoparticles exhibited a release of about 65% within 6 days. This could be due to the lack of interactions of propranolol with the silk fibroin as well as to the hydrophilic properties of propranolol. Curcumin, as a hydrophobic drug, was possibly attached to silk fibroin via hydrophobic interactions and π-π stacking, and presented a reduced release rate compared with that of the hydrophilic drug propranolol [4, 12, 30] . Pramipexole was expected to be attached to silk fibroin through strong electrostatic interactions attributed to the -NH 2 groups, which could have resulted in the decreased release rate. 
Modification of SF with Bovine Serum Albumin and Magnetic Nanoparticles
In order to enhance the properties of silk fibroin nanoparticles, SFm-NPs and silk fibroin-bovine serum albumin nanoparticles (SF-BSA-NPs) were prepared via the introduction of magnetic nanoparticles (Fe 3 O 4 ) and BSA during the silk fibroin nanoparticle formulation, and the drug encapsulation and release efficiency of these silk fibroin nanoparticles were examined in detail. Since propranolol presented the highest encapsulation and release performance, it was used as the model drug for the performance of the two modified types of silk fibroin nanoparticles.
Characterization of Modified Nanoparticles
DLS measurements for silk fibroin-bovine serum albumin nanoparticles and magnetic silk fibroin nanoparticles are presented in Table 5 . Both samples indicated a small polydispersity index of 0.30 and 0.36, respectively, indicating a uniform diameter distribution of nanoparticles. SFm-NPs = magnetic silk fibroin nanoparticles; SF-BSA-NPs = silk fibroin-bovine serum albumin nanoparticles.
The encapsulation efficiency of magnetic silk fibroin and silk fibroin-bovine serum albumin nanoparticles is presented in Table 6 . From the Table, it can be seen that the modification of silk fibroin with magnetic nanoparticles and bovine serum albumin increased the drug encapsulation compared to the pure silk fibroin nanoparticles. Propranolol is a hydrophilic drug and the presence of bovine serum albumin makes the silk fibroin-bovine serum albumin nanoparticles more hydrophilic; for this reason the encapsulation efficiency was increased. Also, the increased encapsulation efficiency of magnetic silk fibroin loaded with propranolol may be attributed to the adsorption of propranolol on Fe 3 O 4 . The surface morphology of magnetic silk fibroin particles and the silk fibroin-bovine serum albumin nanoparticles as well as their encapsulated-with-propranolol counterparts, illustrated by SEM images, is presented in Figure 5 . The magnetic silk fibroin (SFm) and silk fibroin-bovine serum albumin nanoparticles (SF-BSA) exhibited a spherical shape with a diameter of about 288 nm, while the propranolol-encapsulated silk fibroin-bovine serum albumin nanoparticles (SF-BSA + propranolol) and propranolol-encapsulated magnetic silk fibroin nanoparticles (SFm + propranolol) exhibited a particle size of about 384 nm and 490 nm, respectively ( Figure 5 ). The 2θ diffraction peak presented in the XRD pattern of the magnetic silk fibroin nanoparticles (Figure 6a) , that appeared at 2θ = 19.2 • , could be attributed to silk I, a random coil of silk fibroin, while for the encapsulated-with-propranolol magnetic silk fibroin nanoparticles, the characteristic peak at 2θ = 20.7 • could be attributed to silk II, a β-sheet of fibroin. In addition, diffraction peaks corresponding to the (3 1 1), (4 0 0), and (4 4 0) planes of the cubic crystal structure (fcc) of Fe 3 O 4, show the formation of magnetic silk fibroin nanoparticles [19] . The aforementioned XRD results are in agreement with the FTIR results.
Prior to the measurements, the instrument was calibrated against a NIST-certified Ni standard. Each sample had approximately the same dimensions and an additional calibration procedure was performed in order to minimize shape effects. All measurements were performed in a controlled room temperature of 22 • C and consisted of a gradual increase of the applied external magnetic field up to about +1.9 T (µ 0 H) then down to −1.9 T and again up to +1.9 T while measuring the magnetic moment of the sample. The magnetic properties are attributed to the Fe 3 O 4 particles and the overall appearance of the loop is typical for nanoparticles of that composition and size. All measurements have exactly the same appearance, i.e., initial slope, curvature, and saturation plateau, indicating that there are no significant differences in the Fe 3 O 4 particles between the samples and that the procedure for the preparation of the magnetic silk fibroin nanoparticles (SFm-NPs) does not affect significantly the magnetic properties of the Fe 3 O 4 particles. Remanence, Mr, the Mass Magnetization which corresponds to a zero field after the first application of the maximum external field equals to 5-7% of the saturation magnetization and coercivity, µ 0 H c , the reverse external field which zeroes the magnetic moment of the sample is about 0.01 T. Both the remanence and the coercivity are very low in all cases as expected for a soft ferromagnetic material. Saturation magnetization, the maximum Mass Magnetization which could be observed, was obtained for the sample via extrapolation from data of Figure 6b ,c and was found to be σ s = 27.0 (8b) and 27.9 (8c) emu/g. These results correspond to about 50% wt. Fe 3 O 4 content, since the saturation magnetization depends on the Fe 3 O 4 content which is diluted in the silk fibroin, confirmed that Fe 3 O 4 particles are successfully incorporated into the silk fibroin and that their magnetic properties are preserved after drug encapsulation. FTIR results of silk fibroin-bovine serum albumin nanoparticles and propranolol-encapsulated silk fibroin-bovine serum albumin nanoparticles are presented in Figure 7a ,b, respectively, and the characteristic peaks are presented in Table 7 . The bands at 1645 cm −1 and 1491 cm −1 are due to the BSA modification and can be attributed to amide I (C=O stretching) and amide II (C-N stretching and N-H bending) vibrations of BSA, respectively ( Table 7 ). The bands of BSA at 1392 cm −1 (-CH 2 bending) and~1260 cm −1 (amide III, C-N stretching, and N-H bending) may be overlapped by the bands attributed to silk fibroin [7] . A slight shift in the spectra for the propranolol-loaded nanoparticles could be due to drug binding. In Figure 7c ,d, the FTIR results of fibroin magnetic nanoparticles (SFm) and propranolol-encapsulated fibroin magnetic nanoparticles (SFm + propranolol) are presented, while the characteristic peaks are also presented in detail in Table 7 . The spectra presented characteristic bands at 471 and 588 cm −1 and 506 and 595 cm −1 , respectively, attributed to Fe-O bonds [4] , which confirmed the successful preparation of magnetic silk fibroin nanoparticles (Figure 7c) . From the spectra, the existence of both β-sheets and a-helices for magnetic fibroin nanoparticles could be observed, while for the propranolol-encapsulated silk fibroin magnetic nanoparticles β-sheets could be also observed. Figure 8 . Drug release rate of fibroin nanoparticles, magnetic fibroin nanoparticles, and fibroin-bovine serum albumin nanoparticles encapsulated with propranolol.
Conclusions
Silk fibroin nanoparticles were prepared by an easy and safe-to-manipulate method that is amenable to a wide range of drugs and thus useful for silk-based drug delivery systems. Silk fibroin nanoparticles facilitated the entrapment of model drugs (curcumin, pramipexole, and propranolol) with different molecular weights and hydrophobicities and made drug release controllable. Silk fibroin particles loaded with propranolol exhibited a higher release percentage than those loaded with curcumin or pramipexole. Moreover, modified silk fibroin nanoparticles with magnetic nanoparticles as well as with bovine serum albumin were examined for the enhancement of the propranolol encapsulation and release from these nanoparticles. Magnetic silk fibroin nanoparticles increased the propranolol encapsulation efficiency. The silk fibroin-bovine serum albumin particles increased the encapsulation efficiency as well as the release rate of propranolol and were found to be a promising drug carrier.
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